BioNexus Gene Lab Corp. The company is headquartered in Kuala Lumpur, Malaysia.
| Revenue (TTM) | $3.13M |
| Gross Profit (TTM) | 385,890 |
| EBITDA | $-2.64M |
| Operating Margin | -398.70% |
| Return on Equity | -33.70% |
| Return on Assets | -19.00% |
| Revenue/Share (TTM) | $1.44 |
| Book Value | $3.22 |
| Price-to-Book | 0.32 |
| Price-to-Sales (TTM) | 0.78 |
| EV/Revenue | 0.0255 |
| EV/EBITDA | 629.53 |
| Quarterly Earnings Growth (YoY) | -95.00% |
| Quarterly Revenue Growth (YoY) | -96.60% |
| Shares Outstanding | $2.93M |
| Float | $1.67M |
| % Insiders | 44.72% |
| % Institutions | 0.49% |
Volatility is currently expanding
KUALA LUMPUR, Malaysia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company") today introduced BGLC 1Lab, its laboratory workflow product, and announced its initial launch as a controlled GeneMatrix-focused pilot at its MRNA Scientific Sdn. Bhd. subsidiary.
KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”) today announced the launch of its redesigned corporate website at www.bionexusgenelab.com, providing investors, business partners and other visitors with a more comprehensive view of the Company's operations and development initiatives. The website brings together information about MRNA Scientific's RNA screening business, Chemrex's industrial chemical and composite-materials business, and BioNexus' recent healthcare investments and technology relationships.
Licence of up to 20 years, payable in shares, as Malaysia commits RM1 billion to digitalizing public healthcare Licence of up to 20 years, payable in shares, as Malaysia commits RM1 billion to digitalizing public healthcare
KUALA LUMPUR, Malaysia, July 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company") today announced continued progress toward commercializing the VitaGuard™ molecular residual disease ("MRD") platform in Southeast Asia following a recent working visit to facilities of the Tongshu Gene group ("Tongshu Gene") in Shanghai and Changzhou, China, led by Dr. Muthu Meyyappan, Chief Commercial Officer of Fidelion Diagnostics Pte. Ltd. ("Fidelion").
KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging healthcare platforms, today highlighted its participation in the 2026 China–Malaysia Economic Cooperation Outlook Forum, held on May 21, 2026 at the Mandarin Oriental Hotel in Kuala Lumpur. The forum, held under the theme “Advancing Biotechnology and Healthcare Collaboration towards a China–Malaysia Community with a Shared Future,” brought together government representatives, industry leaders, investors, healthcare professionals, and experts from Malaysia and China to discuss strategic cooperation across biotechnology, healthcare, pharmaceutical development, infrastructure, and related sectors.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BGLC and any ticker you trade — then tracks every position and per-strategy win rate.
